GE HealthCare
HQ US40% share
Market leader in iodinated contrast (Omnipaque/iohexol); its Shanghai plant supplied the majority of US iohexol.
pharmaceutical · input
Iodinated Contrast Media (CT/MRI/Angiography)
Water-soluble iodinated compounds injected to enhance CT scans, MRI, and interventional angiography. Key molecules: Iopromide (Bayer Ultravist), Ioversol (Guerbet Optiray), Iohexol, Iopamidol. Global market ~$1.4B/year. A 2022 supply disruption (Bayer Leipzig flood) exposed severe concentration risk in diagnostic imaging globally.
8
Source countries
5
Companies
1
Goods affected
0
Claims on record
What depends on it
Goods that need this input
1 essential American goods rely on iodinated contrast media (ct/mri/angiography) somewhere upstream in their supply chain.
Where it comes from
Source countries
Share of global supply, by country.
| Country | Share of supply |
|---|---|
| DEGermany (Federal Republic of Germany) | 31% |
| NONorway | 31% |
| ITItaly | 16% |
| IEIreland | 11% |
| CHSwitzerland | 3% |
| CNChina | 3% |
| CACanada | 3% |
| FRFrance | 2% |
Who makes it
Supplier companies
5 companies produce iodinated contrast media (ct/mri/angiography).
Bayer (Radiology)
HQ DE25% share
Maker of Ultravist (iopromide) contrast; Leipzig fill site.
Bracco Imaging
HQ IT18% share
Italian contrast-media maker (Isovue/iopamidol).
Guerbet
HQ FR15% share
French contrast-media specialist (Optiray/ioversol, Dotarem).
LG Chem (NBR Latex)(051910.KS)
HQ KR